Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for MS Relapses
NCT03674099Phase 2Unknown
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of imatinib in multiple sclerosis (MS) (2 arms). Primary endpoint: Functional system score change in the most worsened FSS at 28 days. Status: unknown.
02
Drugs
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03674099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674099.